NYSE: ZTS | Healthcare / Drug Manufacturers / USA |
169.86 | +2.05 | +1.22% | Vol 1.47M | 1Y Perf -17.00% |
Feb 2nd, 2023 13:32 DELAYED |
BID | 169.81 | ASK | 169.88 | ||
Open | 167.27 | Previous Close | 167.81 | ||
Pre-Market | 168.95 | After-Market | - | ||
1.14 0.68% | - - |
Target Price | 207.88 | Analyst Rating | Strong Buy 1.23 | |
Potential % | 21.97 | Finscreener Ranking | ★★+ 47.80 | |
Insiders Trans % 3/6/12 mo. | -100/-100/-100 | Value Ranking | ★★+ 47.88 | |
Insiders Value % 3/6/12 mo. | -100/-100/-100 | Growth Ranking | ★★★★+ 64.10 | |
Insiders Shares Cnt. % 3/6/12 mo. | -100/-100/-100 | Income Ranking | ★★★ 44.14 | |
Price Range Ratio 52W % | 56.33 | Earnings Rating | Sell | |
Market Cap | 79.17B | Earnings Date | 14th Feb 2023 | |
Alpha | 0.01 | Standard Deviation | 0.06 | |
Beta | 0.73 |
Today's Price Range 166.71170.62 | 52W Range 124.15205.31 | 5 Year PE Ratio Range 6.9018.20 |
Summary:
Buy
Technical Indicators: | Buy |
Moving Averages: | Strong Buy |
Performance | |||
---|---|---|---|
1 Week | -0.26% | ||
1 Month | 14.51% | ||
3 Months | 13.88% | ||
6 Months | -6.16% | ||
1 Year | -17.00% | ||
3 Years | 25.04% | ||
5 Years | 118.56% | ||
10 Years | 453.32% |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | 38.48 | |||
ROE last 12 Months | 47.92 | |||
ROA (5Y Avg) | 7.48 | |||
ROA last 12 Months | 16.35 | |||
ROC (5Y Avg) | 15.20 | |||
ROC last 12 Months | 18.35 | |||
Return on invested Capital Q | 4.93 | |||
Return on invested Capital Y | 4.02 | |||
Assets Turnover | 0.50 | |||
Receivables Turnover | 5.60 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
8.40 | ||||
14.76 | ||||
11.35 | ||||
37.70 | ||||
344.10 | ||||
3.91 | ||||
105.54 | ||||
10.00 | ||||
80.34B | ||||
Forward PE | 30.67 | |||
PEG | 0.78 |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
1.30 | ||||
2.30 | ||||
0.54 | ||||
1.45 | ||||
13.10 | ||||
Leverage Ratio | 3.00 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
70.00 | ||||
34.80 | ||||
40.50 | ||||
28.40 | ||||
27.33 |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
6.04B | ||||
12.96 | ||||
8.93 | ||||
8.86 |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
1.02 | ||||
1.50 | ||||
21.19 | ||||
21.64 | ||||
Payout ratio | 22.00 |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q03 2022 | 1.24 | 1.21 | -2.42 |
Q02 2022 | 1.22 | 1.20 | -1.64 |
Q01 2022 | 1.22 | 1.32 | 8.20 |
Q04 2021 | 0.96 | 1.00 | 4.17 |
Q03 2021 | 1.10 | 1.25 | 13.64 |
Q02 2021 | 1.08 | 1.19 | 10.19 |
Q01 2021 | 1.04 | 1.26 | 21.15 |
Q04 2020 | 0.86 | 0.91 | 5.81 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
12/2022 QR | 1.15 | -5.74 | Negative |
12/2022 FY | 4.87 | -2.40 | Negative |
3/2023 QR | 1.38 | -4.17 | Negative |
12/2023 FY | 5.37 | -4.28 | Negative |
Next Report Date | 14th Feb 2023 |
Estimated EPS Next Report | 1.14 |
Estimates Count | 8 |
EPS Growth Next 5 Years % | 10.80 |
Volume Overview | |
---|---|
Volume | 1.47M |
Shares Outstanding | 466.07K |
Shares Float | 470.35M |
Trades Count | 26.27K |
Dollar Volume | 247.32M |
Avg. Volume | 2.31M |
Avg. Weekly Volume | 2.16M |
Avg. Monthly Volume | 2.39M |
Avg. Quarterly Volume | 2.38M |
Zoetis Inc. Class A (NYSE: ZTS) stock closed at 167.81 per share at the end of the most recent trading day (a 1.4% change compared to the prior day closing price) with a volume of 2.88M shares and market capitalization of 79.17B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 11300 people. Zoetis Inc. Class A CEO is Kristin C. Peck.
The one-year performance of Zoetis Inc. Class A stock is -17%, while year-to-date (YTD) performance is 14.51%. ZTS stock has a five-year performance of 118.56%. Its 52-week range is between 124.1483 and 205.305, which gives ZTS stock a 52-week price range ratio of 56.33%
Zoetis Inc. Class A currently has a PE ratio of 8.40, a price-to-book (PB) ratio of 14.76, a price-to-sale (PS) ratio of 11.35, a price to cashflow ratio of 37.70, a PEG ratio of 2.32, a ROA of 16.35%, a ROC of 18.35% and a ROE of 47.92%. The company’s profit margin is 27.33%, its EBITDA margin is 40.50%, and its revenue ttm is $6.04 Billion , which makes it $12.96 revenue per share.
Of the last four earnings reports from Zoetis Inc. Class A, there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $1.14 for the next earnings report. Zoetis Inc. Class A’s next earnings report date is 14th Feb 2023.
The consensus rating of Wall Street analysts for Zoetis Inc. Class A is Strong Buy (1.23), with a target price of $207.88, which is +21.97% compared to the current price. The earnings rating for Zoetis Inc. Class A stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Zoetis Inc. Class A has a dividend yield of 1.02% with a dividend per share of $1.50 and a payout ratio of 22.00%.
Zoetis Inc. Class A has a Buy technical analysis rating based on Technical Indicators (ADX : 8.70, ATR14 : 5.03, CCI20 : 88.49, Chaikin Money Flow : 0.24, MACD : 4.54, Money Flow Index : 76.58, ROC : 4.28, RSI : 67.74, STOCH (14,3) : 70.24, STOCH RSI : 0.48, UO : 64.86, Williams %R : -29.76), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Zoetis Inc. Class A in the last 12-months were: Abhay U. Nayak (Option Excercise at a value of $0), Glenn David (Option Excercise at a value of $2 515 017), Glenn David (Sold 32 390 shares of value $6 149 880 ), Gregory Norden (Option Excercise at a value of $0), Heidi C. Chen (Option Excercise at a value of $0), Kristin C. Peck (Option Excercise at a value of $672 106), Kristin C. Peck (Sold 20 000 shares of value $3 722 908 ), Linda Rhodes (Option Excercise at a value of $0), Louise M. Parent (Option Excercise at a value of $0), Michael B. McCallister (Option Excercise at a value of $0), Paul M. Bisaro (Option Excercise at a value of $0), Robert J. Polzer (Option Excercise at a value of $150 605), Robert J. Polzer (Sold 1 120 shares of value $192 383 ), Roman Trawicki (Option Excercise at a value of $525 060), Roman Trawicki (Sold 6 000 shares of value $1 128 900 ), Roxanne Lagano (Option Excercise at a value of $692 153), Roxanne Lagano (Sold 10 733 shares of value $1 942 735 ), Willie M. Reed (Option Excercise at a value of $0), Willie M. Reed (Sold 1 855 shares of value $301 085 )
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Strong Buy | Strong Buy | Strong Buy |
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
CEO: Kristin C. Peck
Telephone: +1 973 822-7000
Address: 10 Sylvan Way, Parsippany 07054, NJ, US
Number of employees: 11 300
Sat, 10 Dec 2022 13:59 GMT Microsoft, Arista among stocks that can survive a triple whammy, Barrons says
- TipRanks. All rights reserved.Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. CBOE EDGX Top real-time data for Premium users, NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Technology and data provided by TeleTrader. Conditions of Use. The regulations of the respective stock are to be observed. Copyright © 2023. All market data is provided by Quotemedia.com. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer. The Cryptocurrency Market real-time data provided by Cryptocompare.com
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.